[go: up one dir, main page]

PE20000633A1 - Combinaciones terapeuticas para la fragilidad musculoesqueletica - Google Patents

Combinaciones terapeuticas para la fragilidad musculoesqueletica

Info

Publication number
PE20000633A1
PE20000633A1 PE1999000522A PE00052299A PE20000633A1 PE 20000633 A1 PE20000633 A1 PE 20000633A1 PE 1999000522 A PE1999000522 A PE 1999000522A PE 00052299 A PE00052299 A PE 00052299A PE 20000633 A1 PE20000633 A1 PE 20000633A1
Authority
PE
Peru
Prior art keywords
etil
pyridin
oxo
tartrate
salt
Prior art date
Application number
PE1999000522A
Other languages
English (en)
Inventor
Hua Zhu Ke
David Duane Thompson
Mei Li
Lydia Codetta Pan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20000633A1 publication Critical patent/PE20000633A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE a)UN MODULADOR SELECTIVO DEL RECEPTOR DE ESTROGENOS (SERM) TAL COMO (-)-CIS-6-FENIL-5-(4-(2-PIRROLIDIN-1-IL-ETOXI)-FENIL)-5,6,7,8-TETRAHIDRONAFTALENO-2-OL O SU SAL D-TARTRATO; b)UN SECRETAGOGO DE LA HORMONA DE CRECIMIENTO TAL COMO 2-AMINO-N-(1(R)-(2,4-DIFLUORO-BENCILOXIMETIL)-2-OXO-2-(3-OXO-3a(R)-PIRIDIN-2-ILMETIL)-2-(2,2,2-TRIFLUORO-ETIL)-2,3,3a,4,6,7-HEXAHIDRO-PIRAZOLO[4,3-c]PIRIDIN-5-IL)-ETIL)-2-METIL-PROPIONAMIDA O SU SAL L-TARTRATO. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE LA FRAGILIDAD MUSCULOESQUELETICA, OSTEOPOROSIS, OSTEOTOMIA, PERDIDA OSEA IDIOPATICA INFANTIL, PERDIDA OSEA ASOCIADA CON PERIODONTITIS, CURACION DE HUESO DESPUES DE UNA RECONSTRUCCION FACIAL, RECONSTRUCCION MAXILAR, RECONSTRUCCION MANDIBULAR
PE1999000522A 1998-06-16 1999-06-11 Combinaciones terapeuticas para la fragilidad musculoesqueletica PE20000633A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8942498P 1998-06-16 1998-06-16

Publications (1)

Publication Number Publication Date
PE20000633A1 true PE20000633A1 (es) 2000-07-26

Family

ID=22217565

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000522A PE20000633A1 (es) 1998-06-16 1999-06-11 Combinaciones terapeuticas para la fragilidad musculoesqueletica

Country Status (29)

Country Link
EP (1) EP1085867A1 (es)
JP (1) JP2002518328A (es)
KR (1) KR20010052817A (es)
CN (1) CN1305378A (es)
AP (1) AP9901581A0 (es)
AR (1) AR018868A1 (es)
AU (1) AU3342099A (es)
BG (1) BG105128A (es)
BR (1) BR9911357A (es)
CA (1) CA2335112A1 (es)
CO (1) CO5070586A1 (es)
EA (1) EA200001189A1 (es)
GT (1) GT199900083A (es)
HR (1) HRP20000857A2 (es)
HU (1) HUP0102395A2 (es)
ID (1) ID26726A (es)
IL (1) IL139587A0 (es)
IS (1) IS5727A (es)
MA (1) MA26648A1 (es)
NO (1) NO20006381L (es)
OA (1) OA11569A (es)
PA (1) PA8472101A1 (es)
PE (1) PE20000633A1 (es)
PL (1) PL345064A1 (es)
SK (1) SK18902000A3 (es)
TN (1) TNSN99118A1 (es)
UY (1) UY25557A1 (es)
WO (1) WO1999065488A1 (es)
ZA (1) ZA993973B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004306A3 (en) * 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen agonists/antagonists
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
JP2004507502A (ja) * 2000-08-30 2004-03-11 ファイザー・プロダクツ・インク 成長ホルモン分泌促進物質のための徐放性製剤
EP1666033B1 (en) * 2001-11-29 2008-12-31 GTX, Inc. Prevention and treatment of androgen-deprivation induced osteoporosis
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
ES2604943T3 (es) 2007-02-09 2017-03-10 Ocera Therapeutics, Inc. Moduladores macrocíclicos del receptor de la grelina y procedimientos de uso de los mismos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
ID26726A (id) 2001-02-01
SK18902000A3 (sk) 2001-12-03
HRP20000857A2 (en) 2001-10-31
IL139587A0 (en) 2002-02-10
JP2002518328A (ja) 2002-06-25
PL345064A1 (en) 2001-11-19
KR20010052817A (ko) 2001-06-25
NO20006381D0 (no) 2000-12-14
AR018868A1 (es) 2001-12-12
UY25557A1 (es) 2001-01-31
HUP0102395A2 (hu) 2001-11-28
GT199900083A (es) 2000-12-05
EA200001189A1 (ru) 2001-06-25
NO20006381L (no) 2000-12-14
BG105128A (en) 2001-11-30
IS5727A (is) 2000-11-24
PA8472101A1 (es) 2000-09-29
CO5070586A1 (es) 2001-08-28
AP9901581A0 (en) 1999-06-30
CN1305378A (zh) 2001-07-25
WO1999065488A1 (en) 1999-12-23
EP1085867A1 (en) 2001-03-28
AU3342099A (en) 2000-01-05
TNSN99118A1 (fr) 2005-11-10
BR9911357A (pt) 2001-03-13
CA2335112A1 (en) 1999-12-23
OA11569A (en) 2004-07-01
MA26648A1 (fr) 2004-12-20
ZA993973B (en) 2000-12-15

Similar Documents

Publication Publication Date Title
BR0110767A (pt) Derivados de piperidina farmaceuticamente ativos, em particular como moduladores da atividade de receptor de quimiocina
ES2069750T3 (es) Metodos y composiciones para curar huesos.
ECSP066313A (es) Derivados de la piridazina y su uso como agentes terapéuticos
ECSP066315A (es) Derivados de la piridazina y su uso como agentes terapéuticos
EA200100154A1 (ru) Бензоциклогептены, способ их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств
AR023130A1 (es) Composiciones para promover el crecimiento
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
BR0315645A (pt) Polipetìdeos de fusão de actrib e seus usos
DE69727158D1 (de) Pharmazeutische zusammensetzungen enthaltend eine mischung von selbstvernetzter und nichtselbstvernetzter hyaluronsäure zur behandlung von arthropathien
MXPA02005173A (es) Composicion farmaceutica para el tratamiento de enfermedades asociadas con disminucion de masa osea.
AR013001A1 (es) Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina.
BR0100558A (pt) Composições e métodos para tratar a osteoporose
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
BRPI0417621A (pt) terapia de combinação contìnua com agonistas seletivos do receptor ep4 de prostaglandina e um estrogênio para o tratamento de estados que se apresentem com baixa massa óssea
BR0310087A (pt) Veìculos sólidos injetáveis para ácido hialurÈnico para aplicação de proteìnas osteogênicas
PE20000644A1 (es) Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
BR0012951A (pt) Agonistas de retinóides seletivos
BR0211932A (pt) Métodos e composições para administração oral de hormÈnio de paratireóide, pth
PE20000633A1 (es) Combinaciones terapeuticas para la fragilidad musculoesqueletica
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
AU2284001A (en) Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone
BRPI0407178A (pt) Composição farmacêutica osteogênica
MXPA04004236A (es) Metodo para la formacion de cristales ibuprofeno.
BRPI0409818A (pt) compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
PE20000646A1 (es) Terapia de combinacion para la fragilidad musculoesqueletica

Legal Events

Date Code Title Description
FD Application declared void or lapsed